Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

KB105

Biologic

KKrystal Biotech, Inc.

KB105 is one of 2 biologic programs targeting Autosomal Recessive Congenital Ichthyosis. It is currently in development.

1

Indications

2

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autosomal Recessive Congenital IchthyosisActive, not recruiting

Autosomal Recessive Congenital IchthyosisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Autosomal Recessive Congenital Ichthyosis

#DrugCompanyPhaseTrials

Accutane

CConrado Roberto Hoffmann Filho

KB105

KKrystal Biotech, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Autosomal Recessive Congenital Ichthyosis2 trials

Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

Unknown status·KKrystal Biotech, Inc.·Phase 1/2·NCT04047732·6 enrolled

Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

Unknown status·KKrystal Biotech, Inc.·Phase 2·NCT05735158·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for KB105. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KB105 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KB105. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Krystal Biotech, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: KKrystal Biotech, Inc.

Related News